Description: ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022.
Home Page: www.prokidney.com
PROK Technical Analysis
2000 Frontis Plaza Blvd.
Winston-Salem,
NC
27103
United States
Phone:
336 999 7028
Officers
| Name | Title |
|---|---|
| Dr. Timothy A. Bertram D.V.M., Ph.D. | Founder, CEO & Director |
| Mr. James Coulston CPA | Chief Financial Officer |
| Dr. Deepak Jain Ph.D. | Chief Operating Officer |
| Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D. | Sr. VP of Investor Relations |
| Mr. Todd C. Girolamo Esq., J.D., M.B.A. | Chief Legal Officer & Corp. Sec. |
| Dr. Libbie P. McKenzie M.D. | Chief Medical Officer |
| Ms. Ashley H. Johns | Sr. VP of Clinical Operations |
| Dr. Joseph M. Stavas M.D. | Sr. VP of Clinical Devel. |
| Dr. Darin J. Weber Ph.D. | Sr. VP of Regulatory Devel. |
| Dr. Kerry Cooper M.D. | Sr. VP of Medical Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 91.3172 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-07-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 59 |